We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+2.21%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.06B
AUM Growth
-$395M
Cap. Flow
-$256M
Cap. Flow %
-5.05%
Top 10 Hldgs %
43.96%
Holding
127
New
13
Increased
22
Reduced
22
Closed
13

Top Buys

Rank Stock Value
1
ITGR icon
Integer Holdings
ITGR
+$40.8M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$39.5M
3
EXAS
Exact Sciences
EXAS
+$29.3M
4
ARGX icon
argenx
ARGX
+$22M
5
AMGN icon
Amgen
AMGN
+$21M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$106M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$104M
3
JANX icon
Janux Therapeutics
JANX
+$60.8M
4
ESPR
Esperion Therapeutics
ESPR
+$36.7M
5
SRRK icon
Scholar Rock
SRRK
+$30.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERA icon
51
Vera Therapeutics
VERA
$2.33B
$24.5M 0.48%
675,872
– –
SCPH
52
DELISTED
scPharmaceuticals
SCPH
$24.2M 0.48%
5,559,528
– –
REGN icon
53
Regeneron Pharmaceuticals
REGN
$73B
$24M 0.47%
22,800
– –
MLYS icon
54
Mineralys Therapeutics
MLYS
$2.35B
$23.7M 0.47%
2,021,424
– –
IMTX icon
55
Immatics
IMTX
$1.18B
$23.3M 0.46%
2,006,381
+236,673
+13% +$2.67M
HRTX icon
56
Heron Therapeutics
HRTX
$92.3M
$22.8M 0.45%
6,512,866
-3,598,684
-36% -$11.1M
CMPX icon
57
Compass Therapeutics
CMPX
$355M
$22.4M 0.44%
22,362,850
– –
MORF
58
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$20.9M 0.41%
612,500
+54,000
+10% +$1.6M
VIR icon
59
Vir Biotechnology
VIR
$1.45B
$20.6M 0.41%
2,320,102
+1,680,102
+263% +$16.1M
CGEM icon
60
Cullinan Oncology
CGEM
$1.03B
$20M 0.4%
1,147,655
+630,049
+122% +$13.4M
SLRN
61
DELISTED
ACELYRIN
SLRN
$17.6M 0.35%
4,001,711
– –
APGE icon
62
Apogee Therapeutics
APGE
$10.1B
$14.9M 0.29%
379,130
-339,771
-47% -$16.5M
NMRA icon
63
Neumora Therapeutics
NMRA
$308M
$14.7M 0.29%
1,500,000
– –
ACET icon
64
Adicet Bio
ACET
$76M
$13.9M 0.27%
715,446
– –
ADCT icon
65
ADC Therapeutics
ADCT
$140M
$13.6M 0.27%
+4,316,824
New +$17.2M
CRVS icon
66
Corvus Pharmaceuticals
CRVS
$1.1B
$12.6M 0.25%
6,943,654
– –
ABCL icon
67
AbCellera Biologics
ABCL
$1.62B
$12.4M 0.24%
4,180,768
– –
TYRA icon
68
Tyra Biosciences
TYRA
$1.81B
$12.3M 0.24%
768,638
– –
TELA icon
69
TELA Bio
TELA
$30.9M
$11.6M 0.23%
2,457,542
-378,000
-13% -$1.99M
ALXO icon
70
ALX Oncology
ALXO
$261M
$11.4M 0.23%
1,894,462
-823,508
-30% -$10.1M
RPTX
71
DELISTED
Repare Therapeutics
RPTX
$11M 0.22%
3,322,488
– –
SOLV icon
72
CALL
Solventum
SOLV
$15.2B
$10.6M 0.21%
+200,000
New +$12.1M
PMVP icon
73
PMV Pharmaceuticals
PMVP
$58.1M
$10.5M 0.21%
6,475,291
– –
LXRX icon
74
Lexicon Pharmaceuticals
LXRX
$1.03B
$9.82M 0.19%
5,846,100
+2,304,100
+65% +$4.13M
LYEL icon
75
Lyell Immunopharma
LYEL
$319M
$9.29M 0.18%
320,255
+310,280
+3,111% +$14.8M
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2024 Portfolio in Review

As of Q2 2024, OrbiMed held 127 positions worth $5.06B, down 7.2% from $5.46B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

OrbiMed withdrew a net $256M in Q2 2024, closing 13 positions and reducing 22 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

Against the trend, OrbiMed opened a new position in Integer Holdings worth $40.4M.

  • OrbiMed's largest Q2 2024 buy was Integer Holdings: 349,221 shares worth $40.4M.
  • OrbiMed added most to Exact Sciences in Q2 2024, an estimated $29.3M increase.
  • OrbiMed's biggest Q2 2024 reduction was BioMarin Pharmaceuticals, cutting an estimated $104M.
  • OrbiMed fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $106M.
  • OrbiMed's ten largest holdings make up 44% of its $5.06B portfolio in Q2 2024.
  • OrbiMed opened 13 new positions and closed 13 in Q2 2024.
  • OrbiMed's portfolio value fell 7.2% quarter-over-quarter to $5.06B.

Based on OrbiMed's 13F filing for Q2 2024, filed 14 Aug 2024.